Editor's Note: Can PDE5 inhibitors inhibit fibrosis? Is this a direct effect of PDE5 inhibitors on the fibrotic cascade? If this hypothesis is found true, then an entire new algorithm for treatment of ED and other diseases may be realized. Three recent manuscripts this year discuss this question. Dr Jackie Corbin, a renowned PDE5 expert, offers a perspective in light of its potential clinical relevance.
: 517-528) suggest beneficial effects of chronic elevation in tissue cGMP levels for treating diseases associated with fibrotic lesions such as Peyronie's disease, diabetes, and right ventricular hypertrophy. Doses of sildenafil that were nearly equivalent to those given to men with erectile dysfunction were antifibrotic in rat penile tunica albuginea after several weeks of treatment. In addition, this treatment increased cavernosal endothelial and smooth muscle cells and decreased TGFb1 expression. The latter protein is believed to inhibit smooth muscle growth. In fibroblast cultures, similar antifibrotic-like effects were observed with sildenafil, L-arginine, or 8-Br-cGMP treatment, and it was presumed that each acted by causing elevation in cGMP levels or by mimicking cGMP. Elevation in cAMP by pentoxifylline was also effective. It is not surprising that cGMP and cAMP elevation caused a similar effect since these two cyclic nucleotides are known to produce the same effects in many, although not all, signaling pathways in which they participate. A new PDE5 inhibitor, DA-8159 from the Dong-A Pharmaceutical Company, was also antifibrotic for penile corpus cavernosum when administered to streptozotocin diabetic rats or for right ventricular myocardium when administered to rats made pulmonary hypertensive by monocrotaline treatment. Again, the results imply that chronic elevation in tissue cGMP levels in the affected tissues could be beneficial in preventing or reducing fibrosis in some human tissues. The mechanisms for the apparent cyclic nucleotide effects are uncertain, but the modifications in each study suggest that long-term cyclic nucleotide elevation in these tissues modifies either gene expression or protein synthesis/degradation to produce the effects. Perhaps vasodilation caused by cGMP elevation improves corporal oxygenation, which prevents tissue deterioration. The results so far are very encouraging, although the apparent alteration in cellular protein profiles that takes place could potentially cause some undesirable effects in addition to the beneficial effects observed.
